ForNRG1/2gene fusion solid tumors, if standard treatment fails, it is recommended to participation in related clinical trials for pan-ERBB TKIs such as afatinib and tarloxotinib, or ERBB2 inhibitory mAbs, ERBB3 inhibitory mAbs or dual anti-ERBB2/ERBB3 mAbs such as zenocutuzumab. ForNRG1/2gene fusion tumor patients with drug resistance, performing NGS test to identify resistance mechanisms and deciding whether other related clinical trials are appropriate is recommended. The gene discussed is EGFR; the disease is neoplasm.